{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:26:59Z","timestamp":1787009219688,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9-10","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dupuytren\u2019s contracture is a connective tissue disease characterized by an abnormal proliferation of collagen in the palm and fingers, which leads to a decline in hand function because of progressive joint flexion. In addition to surgical and percutaneous interventions, collagenase clostridium histolyticum (CCH, trade name Xiaflex) is an intralesional enzymatic treatment for adults with palpable cords. The objectives of this study are to evaluate factors predictive of recurrence following treatment with CCH and to review the outcomes of repeat treatments with CCH for recurrent contracture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>An institutional review board\u2013approved retrospective chart review was conducted for patients between 2010 and 2017 who received CCH injections for Dupuytren\u2019s contracture at a Veterans Affairs hospital. Demographics, comorbidities, affected finger and joint, pre\/posttreatment contracture, time to recurrence, and treatment of recurrence were recorded. Successful treatment was defined as contracture \u22645\u00b0 following CCH, and improvement was defined as \u226520\u00b0 reduction from baseline contracture. Study cohorts were followed after their secondary treatment, and time to recurrence was recorded and plotted using a Kaplan\u2013Meier curve. A Cox proportional hazards model was used to compare treatment group risk factors for recurrence with a P-value less than .05 defined as statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 174 injections performed for the correction of flexion deformities in 109 patients, 70% (121) were successfully treated with CCH, and an additional 20% (35) had improvement. There was a recurrence of contractures in 43 joints (25%). Of these, 16 contractures were treated with repeat CCH, whereas another 16 underwent limited fasciectomy. In total, 75% (12 of 16) of the repeat CCH group and 75% of the fasciectomy group were successfully treated. Pre-injection contracture of \u226525\u00b0 was found to be predictive of recurrence (P\u2009&amp;lt;\u2009.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial treatment of contracture with CCH had a 70% success rate with 25% recurrence during the study period. Compared with limited fasciectomy, CCH had decreased efficacy. Based on the findings of this study, we believe that the treatment of primary and\/or recurrent Dupuytren\u2019s contracture with CCH is a safe and less invasive alternative to fasciectomy in the era of telemedicine. CCH treatment requires no suture removal, which allows the ability to assess motion virtually, and the potential consequences of CCH treatment such as skin tears can be assessed and managed conservatively. In the veteran and active duty population, CCH can facilitate faster recovery and return to service. Strengths of this study include a large series of veteran populations with longitudinal follow-up to determine treatment efficacy for primary Dupuytren\u2019s contracture and recurrence. Limitations include a smaller sample size compared to previous trials, a lack of standardized follow-up, and the retrospective nature of our study that prohibits randomization to compare outcomes between CCH treatment and fasciectomy efficacy over time. Directions for future research include stratification of patients by joint and specific digit involvement as well as comparison with percutaneous needle fasciotomy, another minimally invasive technique that could benefit the veteran population at increased risk for developing Dupuytren\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/milmed\/usad075","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T11:20:28Z","timestamp":1678965628000},"page":"e2975-e2981","source":"Crossref","is-referenced-by-count":8,"title":["Dupuytren\u2019s Contracture Recurrence and Treatment Following Collagenase Clostridium Histolyticum Injection: A Longitudinal Assessment in a Veteran Population"],"prefix":"10.1093","volume":"188","author":[{"given":"Rakel M","family":"Zarb","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Medical College of Wisconsin , Wauwatosa, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R","family":"Graf","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Medical College of Wisconsin , Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8951-9268","authenticated-orcid":false,"given":"Jacob E","family":"Talhelm","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Medical College of Wisconsin , Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C","family":"Stehr","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Medical College of Wisconsin , Wauwatosa, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Sanger","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Medical College of Wisconsin , Wauwatosa, WI 53226, USA"},{"name":"Department of Plastic Surgery, Clement J. Zablocki Veterans Administration Medical Center , Milwaukee, WI 53295, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani S","family":"Matloub","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Medical College of Wisconsin , Wauwatosa, WI 53226, USA"},{"name":"Department of Plastic Surgery, Clement J. Zablocki Veterans Administration Medical Center , Milwaukee, WI 53295, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Daley","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Medical College of Wisconsin , Milwaukee, WI 53226, USA"},{"name":"Department of Orthopaedic Surgery, Clement J. Zablocki Veterans Administration Medical Center , Milwaukee, WI 53295, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"1","key":"2023083018185849600_R1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bmb\/ldw020","article-title":"Collagenase clostridium histolyticum in Dupuytren\u2019s contracture: a systematic review","volume":"118","author":"Smeraglia","year":"2016","journal-title":"Br Med Bull"},{"issue":"1","key":"2023083018185849600_R2","doi-asserted-by":"publisher","first-page":"240e","DOI":"10.1097\/PRS.0000000000002857","article-title":"Evidence-based medicine: options for Dupuytren\u2019s contracture: incise, excise, and dissolve","volume":"139","author":"Denkler","year":"2017","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"2023083018185849600_R3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40259-017-0211-z","article-title":"Adverse effects of collagenase in the treatment of Dupuytren disease: a systematic review","volume":"31","author":"Sanjuan-Cerver\u00f3","year":"2017","journal-title":"BioDrugs"},{"issue":"10","key":"2023083018185849600_R4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jhsa.2016.07.090","article-title":"The impact of collagenase clostridium histolyticum introduction on Dupuytren treatment patterns in the United States","volume":"41","author":"Zhao","year":"2016","journal-title":"J Hand Surg"},{"issue":"8","key":"2023083018185849600_R5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.jhsa.2015.04.036","article-title":"Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year data","volume":"40","author":"Peimer","year":"2015","journal-title":"J Hand Surg"},{"key":"2023083018185849600_R6","doi-asserted-by":"publisher","DOI":"10.1097\/01.prs.0000445884.26971.23","article-title":"Treatment of Dupuytren disease with injectable collagenase in a veteran population: a case series at the Department of Veterans Affairs New Jersey Health Care System","volume":"14","author":"Sood","year":"2014","journal-title":"Eplasty"},{"issue":"2","key":"2023083018185849600_R7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jhsg.2018.12.0058","article-title":"Cost per episode of care with collagenase clostridium histolyticum versus fasciectomy for Dupuytren contracture: a real-world claims database analysis","volume":"1","author":"Camper","year":"2019","journal-title":"J Hand Surg Glob Online"},{"issue":"10","key":"2023083018185849600_R8","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.jhsa.2015.06.099","article-title":"The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study","volume":"40","author":"Gaston","year":"2015","journal-title":"J Hand Surg"},{"issue":"1","key":"2023083018185849600_R9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jhsa.2013.10.002","article-title":"Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures","volume":"39","author":"Coleman","year":"2014","journal-title":"J Hand Surg"},{"key":"2023083018185849600_R10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/CEOR.S269957","article-title":"Healthcare costs and resource use of patients with Dupuytren contracture treated with collagenase clostridium histolyticum or fasciectomy: a propensity matching analysis","volume":"12","author":"Zah","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"2023083018185849600_R11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164849","article-title":"Recurrence of Dupuytren\u2019s contracture: a consensus-based definition","volume":"12","author":"Kan","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"2023083018185849600_R12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamasurg.2016.3605","article-title":"Treatment of Dupuytren contracture with injectable collagenase within the Veterans Affairs system","volume":"152","author":"Duquette","year":"2017","journal-title":"JAMA Surg"},{"key":"2023083018185849600_R13","article-title":"VA Utilization Profile FY 2017 Veterans Affairs","volume-title":"VA.gov.","author":"United States Department of Veterans Affairs"},{"key":"2023083018185849600_R14","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-1243-z","article-title":"Prevalence, predictors and economic consequences of no-shows","volume":"16","author":"Kheirkhah","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2023083018185849600_R15","doi-asserted-by":"publisher","DOI":"10.5888\/pcd15.170168","article-title":"Telemedicine in the management of type 1 diabetes","volume":"15","author":"Xu","year":"2018","journal-title":"Prev Chronic Dis"},{"issue":"12","key":"2023083018185849600_R16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010143.pub2","article-title":"Surgery for Dupuytren\u2019s contracture of the fingers","volume":"2015","author":"Rodrigues","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2023083018185849600_R17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/1753193410376286","article-title":"The outcome of surgical treatments for primary Dupuytren\u2019s disease\u2014a systematic review","volume":"35","author":"Becker","year":"2010","journal-title":"J Hand Surg Eur Vol"},{"issue":"5","key":"2023083018185849600_R18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1177\/1753193419900483","article-title":"Recurrent Dupuytren\u2019s disease after fasciectomy and collagenase injection are histologically indistinguishable","volume":"45","author":"Sanjuan-Cervero","year":"2020","journal-title":"J Hand Surg Eur Vol"},{"key":"2023083018185849600_R19","doi-asserted-by":"publisher","DOI":"10.1177\/15589447211043204","article-title":"Dupuytren cords do not undergo significant histopathological change after collagenase clostridium histolyticum injection","author":"Guo","year":"2022","journal-title":"Hand (N Y)"},{"issue":"6","key":"2023083018185849600_R20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/1753193415626113","article-title":"Does collagenase injection disrupt or digest the Dupuytren\u2019s cord: a magnetic resonance imaging study","volume":"41","author":"Crivello","year":"2016","journal-title":"J Hand Surg Eur Vol"},{"issue":"5","key":"2023083018185849600_R21","doi-asserted-by":"publisher","first-page":"391.e1","DOI":"10.1016\/j.jhsa.2017.02.010","article-title":"Treatment of recurrent Dupuytren contracture in joints previously effectively treated with collagenase clostridium histolyticum","volume":"42","author":"Bear","year":"2017","journal-title":"J Hand Surg Am"},{"issue":"6","key":"2023083018185849600_R22","doi-asserted-by":"publisher","first-page":"1000e","DOI":"10.1097\/PRS.0000000000001282","article-title":"Salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum","volume":"135","author":"Eberlin","year":"2015","journal-title":"Plast Reconstr Surg"},{"issue":"7","key":"2023083018185849600_R23","doi-asserted-by":"publisher","first-page":"e657","DOI":"10.3928\/01477447-20140626-64","article-title":"Multiple collagenase injections are safe for treatment of Dupuytren\u2019s contractures","volume":"37","author":"Gajendran","year":"2014","journal-title":"Orthopedics"},{"issue":"5","key":"2023083018185849600_R24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/1753193413488305","article-title":"Surgical findings in the treatment of Dupuytren\u2019s disease after initial treatment with clostridial collagenase (Xiaflex)","volume":"39","author":"Hay","year":"2014","journal-title":"J Hand Surg Eur Vol"},{"issue":"2","key":"2023083018185849600_R25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/SAP.0000000000001068","article-title":"Outcome of Dupuytren contractures after collagenase clostridium histolyticum injection: a single-institution experience","volume":"79","author":"Hwee","year":"2017","journal-title":"Ann Plast Surg"},{"issue":"3","key":"2023083018185849600_R26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012943","article-title":"Collagenase injections for Dupuytren\u2019s disease: prospective cohort study assessing 2-year treatment effect durability","volume":"7","author":"Lauritzson","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"2023083018185849600_R27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00402-019-03120-y","article-title":"Factors predicting the 1-year outcome of collagenase treatment for Dupuytren\u2019s disease","volume":"139","author":"Scheibler","year":"2019","journal-title":"Orthop Trauma Surg"},{"issue":"1","key":"2023083018185849600_R28","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-019-2712-z","article-title":"Hand therapy or not following collagenase treatment for Dupuytren\u2019s contracture? Protocol for a randomised controlled trial","volume":"20","author":"Aglen","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"2023083018185849600_R29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11552-013-9540-7","article-title":"Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren\u2019s contracture","volume":"8","author":"Naam","year":"2013","journal-title":"Hand (N Y)"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/188\/9-10\/e2975\/51307444\/usad075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/188\/9-10\/e2975\/51307444\/usad075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T14:19:05Z","timestamp":1693405145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/188\/9-10\/e2975\/7078899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":29,"journal-issue":{"issue":"9-10","published-online":{"date-parts":[[2023,3,16]]},"published-print":{"date-parts":[[2023,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usad075","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,3,16]]}}}